Project/Area Number |
24590446
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Human pathology
|
Research Institution | Oita University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
YANAGIHARA Kazuyoshi 国立研究開発法人国立がん研究センター, 臨床開発センター (20158025)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 胃癌 / 20q13 / DDX27 / 治療 / 20番染色体 |
Outline of Final Research Achievements |
Previously, we have reported that gain at chromosome 20q13 is the most common genomic copy number aberration in gastric cancer (GC) (29/30 cases), and that among the genes located in this region, we have identified DDX27 as a candidate target for GC. Here, we analyzed the significance of DDX27 upregulation in GC cells. We found that DDX27 was frequently upregulated in GC tissues, and significantly associated with venous invasion and liver metastasis. Furthermore, high expression of DDX27 was independently associated with poorer prognosis. Knockdown of DDX27 reduced the ability of GC cells to form colonies, but had little effect on their invasiveness. We also found that knockdown of DDX27 reduced the viability of GC cells through inhibition of cell cycle progression independently of apoptosis. Thus, our results suggest that expression of DDX27 contributes to colony formation by GC cells through cell cycle control and may be a potential therapeutic target for GC patients.
|